{"type":"trials","record":{"id":87095,"source_id":"isrctn","external_id":"ISRCTN16566739","title":"An early-stage study to see if U8:ranibizumab eye drops are safe, well-tolerated, and effective for patients with a specific eye condition called choroidal neovascularisation","brief_summary":"Primary objective: To assess the safety and tolerability of topical U8:ranibizumab 8.5 mg/ml eye drops Secondary objective: To assess the efficacy of U8:ranibizumab 8.5 mg/ml eye drops","overall_status":"Recruiting","phases":["Phase I"],"study_type":"Interventional","sponsor":"University College London","enrollment":0,"countries":["United Kingdom","England"],"start_date":"2026-05-20","completion_date":"2026-12-31","last_update_date":"2026-07-02","source_url":"https://www.isrctn.com/ISRCTN16566739","editorial_summary":"A registered Phase I study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T03:46:39.792962+00:00","last_seen_at":"2026-09-25T03:46:39.551+00:00","metadata":{"sex":"All","age_range":"Mixed","comparator":null,"attribution":"Source: ISRCTN ISRCTN16566739; retrieved 2026-09-25","interventions":["Ranibizumab","Drug"],"reuse_license":"Registry contribution CC BY 4.0; generated metadata CC0","registry_source":"ISRCTN","outcome_measures":["Observations relating to local ocular tolerability, including: visual analogue scale (VAS) scores for comfort, slit lam…","Secondary efficacy endpoint and outcome measures: Patterns of disease activity that may need for retreatment where the…"],"design_description":"Interventional","source_has_results":false},"controlled_terms":["Wet age-related macular degeneration","U8:ranibizumab 8.5 mg/ml eye drops – a single daily dose for 12 weeks","Ranibizumab","Drug"],"relevance_confidence":60,"source_quality_score":98,"freshness_score":100,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T03:46:42.633202+00:00","duplicate_cluster_key":"id:isrctn16566739","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2026-05-20 to 2026-12-31","comparator":null,"confidence":"structured-source","population":"All · Mixed","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T03:46:39.554Z","intervention":["Ranibizumab","Drug"],"participants":0,"study_design":"Interventional","subject_scope":"Human clinical study registration","evidence_stage":"Phase I","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Observations relating to local ocular tolerability, including: visual analogue scale (VAS) scores for comfort, slit lam…","Secondary efficacy endpoint and outcome measures: Patterns of disease activity that may need for retreatment where the…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as Interventional."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ISRCTN Registry","homepage_url":"https://www.isrctn.com/"}},"canonical_url":"https://www.immortal.life/trials/87095","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}